Certain embodiments of the invention include methods and compositions for evaluating flaviviruses, such as Zika virus, for the purpose of identifying, typing, and/or categorizing/speciation of virus in samples using nucleic acid sequencing.

Provided herein are Zika virus (ZIKV) binding constructs, e.g., antibodies and antigen-binding fragments thereof and antibody mimetics, as well as related conjugates, polypeptides, nucleic acids, expression vectors, host cells, kits, and assay systems. Methods detecting ZIKV infection and/or ZIKV exposure and/or ZIKV immunity are provided.

Provided is an isolated binding protein including an antigen binding domain binding to an NS1 protein, and including specific heavy chain CDR and light chain CDR. The binding protein can specifically identify and bind to NS1, and has relatively high sensitivity and specificity, so as to detect dengue vims. Moreover, the binding protein does not need to be produced by injecting hybridoma cells into mouse peritoneal cavity, while simplifying production, thus stabilizing antibody functionality.

A method for providing immunoassay test results includes collecting at least one biologic with a testing device, conjugating the biologic with particles on a conjugate pad of a test strip to create an immune complex, binding antigens or antibodies of the immune complex to antigens or antibodies of a test line, providing a software application to be stored on a mobile device having a camera; capturing an image of the testing device, including a color mosaic having at least one color value corresponding to a positive test result, comparing the color values of the test line image to the color values of the image of the color mosaic, determining if the color values of the image of the test line are within a predetermined range of the at least one color value of the image of the color mosaic corresponding to a positive test result; and presenting test results on the viewing screen.

The present invention is within the Molecular Biology and Biochemistry and Biotechnology fields. More specifically, the present invention describes a process for producing the recombinant fragment of the c-terminal region of the flavivirus NS1 non-structural soluble protein and the recombinant protein (Zv-ΔNS1) in large scale. The product of the invention has advantageous characteristics as a result of the process for obtaining the same, notably regarding folding and the immunological characteristics suitable for the development of serological tests to detect Zika virus. There are also described a purification process, its use and a method of detecting interaction, and a method of diagnosing diseases caused by a flavivirus.

Disclosed are lateral flow assay methods, lateral flow assay test strips, and devices for detection of antibody classes associated with acute immune responses. The invention generally relates to assay methods, in particular, lateral flow assay methods for detection of an antibody isotype associated with acute infection, and to lateral flow assay strips for use in the methods of the invention.

Proteases of Group IV (+)ssRNA viruses were found to act on a human sequences in addition to the viral sequences. The identity of the cleavable human sequences is disclosed. Detection of these sequences can act as a diagnostic of infection. It is contemplated that these findings could be employed to facilitate post-translational silencing at the level of protein (e.g., removal of existing proteins), thus serving as a protein analog to CRISPR/Cas9 and RNAi/RISC, and further to enable sequence-specific silencing of host functions without the modification of the host genome.

Disclosed herein are recombinant baculoviruses suitable for detecting the presence of arthropod-borne viruses in a biological sample of a test subject. The information derived from the detection may also be used to render a diagnosis on whether the test subject is infected with the arthropod-borne viruses or not, so that proper course of treatment may be assigned to the subject.

There is provided a method of identifying a flavivirus infection selected from Zika virus (ZIKV), Dengue virus (DENV) and combination thereof in a subject, the method comprising determining whether a sample of the subject reacts with a peptide associated with a certain relative binding capacity. Also claimed are kits, isolated peptides, immune system stimulating compositions comprising specific peptides and a method of distinguishing ZIKV infection from DENV infection.

Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.